Diaxonhit SA Stock Other OTC
Stocks
FR0004054427
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other OTC
|
||
| - USD | - |
|
| 09-24 | Eurobio Scientific Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 09-17 | EB Development Plans to Delist Eurobio Scientific by Late September |  |
| Market Cap | 253M 284M 236M 215M 405M 27.34B 409M 2.85B 1.11B 13.98B 1.07B 1.04B 44.86B | P/E 2026 * |
22.2x | P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 221M 248M 206M 188M 354M 23.88B 357M 2.49B 966M 12.21B 933M 912M 39.18B | EV / Sales 2026 * |
1.25x | EV / Sales 2027 * | - |
| Free-Float |
98.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | 58 | 2023-06-12 |
Olivier Bosc
DFI | Director of Finance/CFO | - | 2023-10-09 |
Maarten Penning
CTO | Chief Tech/Sci/R&D Officer | - | 2023-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 2018-12-31 | |
Michel Picot
BRD | Director/Board Member | 73 | 2019-06-26 |
| Director/Board Member | 69 | 2017-06-14 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | +3.04% | +49.37% | +94.17% | 74.41B | |
| -3.11% | -2.32% | +23.28% | +77.03% | 59.26B | |
| +0.89% | -0.77% | +5.80% | +32.89% | 47.14B | |
| -0.96% | -4.50% | +26.36% | +33.18% | 42.91B | |
| +0.36% | +0.81% | +352.17% | +689.61% | 44.13B | |
| -0.20% | -0.77% | +3.74% | +100.60% | 40.79B | |
| -0.54% | +2.93% | +9.50% | +50.41% | 30.77B | |
| -2.68% | +5.11% | +33.11% | +19.50% | 29.31B | |
| +2.33% | -5.69% | -27.28% | +338.00% | 23.71B | |
| Average | +0.03% | -0.79% | +52.89% | +159.49% | 43.6B | |
| Weighted average by Cap. | +0.24% | -0.98% | +58.02% | +150.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 176M 198M 164M 150M 282M 19.03B 285M 1.99B 770M 9.73B 743M 727M 31.22B | - |
| Net income | 11.6M 13.06M 10.83M 9.87M 18.61M 1.26B 18.78M 131M 50.77M 642M 49.02M 47.95M 2.06B | - |
| Net Debt | -32M -36.02M -29.87M -27.22M -51.34M -3.46B -51.82M -361M -140M -1.77B -135M -132M -5.68B | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
